EDV nanocell therapy with chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic cancer that is confirmed by a biopsy or tissue sample.
- You have received only one prior chemotherapy regimen (FOLFIRINOX or NALIRIFOX) and your cancer got worse during or within 3 months of ending that treatment.
- You are 18 years or older and your tumors have a protein called EGFR.
- You are in relatively good health (able to do daily activities, with adequate organ function).
- You are not pregnant or breastfeeding and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called MT-601 for people with advanced pancreatic cancer that has not worsened during standard chemotherapy (FOLFIRINOX or nab-paclitaxel/gemcitabine). The goal is to see if this new treatment can help control the cancer.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Hear when a new Pancreatic Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.